Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023

Detalles Bibliográficos
Autores principales: Link-Gelles, Ruth, Ciesla, Allison Avrich, Roper, Lauren E., Scobie, Heather M., Ali, Akilah R., Miller, Joseph D., Wiegand, Ryan E., Accorsi, Emma K., Verani, Jennifer R., Shang, Nong, Derado, Gordana, Britton, Amadea, Smith, Zachary R., Fleming-Dutra, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Full Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927070/
https://www.ncbi.nlm.nih.gov/pubmed/36730051
http://dx.doi.org/10.15585/mmwr.mm7205e1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927070/
https://www.ncbi.nlm.nih.gov/pubmed/36730051
http://dx.doi.org/10.15585/mmwr.mm7205e1

Ejemplares similares